182 related articles for article (PubMed ID: 33724548)
1. Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer.
Du F; Qiu Z; Ai W; Huang C; Ji J; Xiao X; Zhou J; Fang M; Jiang X; Gao C
J Leukoc Biol; 2021 Aug; 110(2):327-334. PubMed ID: 33724548
[TBL] [Abstract][Full Text] [Related]
2. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
Gou M; Qu T; Wang Z; Yan H; Si Y; Zhang Y; Dai G
J Immunol Res; 2021; 2021():2549295. PubMed ID: 34993252
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
6. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
Fornarini G; Rebuzzi SE; Banna GL; Calabrò F; Scandurra G; De Giorgi U; Masini C; Baldessari C; Naglieri E; Caserta C; Manacorda S; Maruzzo M; Milella M; Buttigliero C; Tambaro R; Ermacora P; Morelli F; Nolè F; Astolfi C; Sternberg CN
ESMO Open; 2021 Jun; 6(3):100118. PubMed ID: 33984678
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
[TBL] [Abstract][Full Text] [Related]
8. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
Ha H; Nam AR; Bang JH; Park JE; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Oncotarget; 2016 Nov; 7(47):76604-76612. PubMed ID: 27780932
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen.
Buyuksimsek M; Kidi MM; Ogul A; Mirili C; Paydas S
J Gastrointest Cancer; 2021 Mar; 52(1):249-255. PubMed ID: 32185743
[TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
[TBL] [Abstract][Full Text] [Related]
13. Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters.
Jia G; Qiu L; Zheng H; Qin B; Sun Z; Shao Y; Yang Z; Shao J; Zhou Y; Jiao S
BMC Cancer; 2023 Jun; 23(1):556. PubMed ID: 37328805
[TBL] [Abstract][Full Text] [Related]
14. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.
Goktas Aydin S; Cakan Demirel B; Bilici A; Topcu A; Aykan MB; Kahraman S; Akbıyık I; Atci MM; Olmez OF; Yaren A; Sendur MAN; Geredeli C; Seker M; Urun Y; Karadurmus N; Aydin A
Curr Med Res Opin; 2022 Oct; 38(10):1751-1758. PubMed ID: 35916475
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients.
Zhang B; Yao W
World J Surg Oncol; 2022 Sep; 20(1):320. PubMed ID: 36171621
[TBL] [Abstract][Full Text] [Related]
16. First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer.
Zhao S; Guo XG; Zhang D; Zhou G; Song P; Yang J; Zhang Y; Li P; Hu Y; Wang P
J Gastroenterol Hepatol; 2021 Dec; 36(12):3541-3547. PubMed ID: 34423859
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective study.
Guo J; Zhou Q; Zhou M; Dai H; Li L; Qiu Y; Mao L; Liu B; Shen J
Cancer Med; 2023 Nov; 12(22):20699-20711. PubMed ID: 37930138
[TBL] [Abstract][Full Text] [Related]
18. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
19. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of coagulation indices for predicting survival in patients with biliary tract cancer.
Ke X; Jin B; You W; Chen Y; Xu H; Zhao H; Lu X; Sang X; Zhong S; Yang H; Mao Y; Du S
BMC Cancer; 2021 Aug; 21(1):953. PubMed ID: 34433454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
